Sibling umbilical cord blood infusion is safe in young children with cerebral palsy

Abstract

Abstract Preclinical and early phase clinical studies suggest that an appropriately dosed umbilical cord blood (CB) infusion has the potential to help improve motor function in young children with cerebral palsy (CP). As many children with CP do not have their own CB available, use of allogeneic cells would extend access to this potentially beneficial therapy to more children. In this phase I, open‐label study, 15 children, aged 1 to 6 years, with moderate to severe spastic CP were treated with a single intravenous infusion of allogeneic human leukocyte antigen (HLA) matched or partially matched sibling CB with a cell dose of ≥2.5 × 107 cells/kg based on the pre‐cryopreservation count (median infused cell dose, 3.3 × 107; range, 1.8‐5.2 × 107). There were a total of 49 adverse events (AEs) over a 2‐year time period, but there were no AEs related to the CB infusions. Specifically, there were no acute infusion reactions and no antibody formation against platelets, red blood cells, or donor‐specific HLA antigens. Donor cells were not detected in peripheral blood 6 months later. Six months after infusion, participants were assessed for response and experienced a mean ± SD increase of 4.7 ± 2.5 points on the Gross Motor Function Measure‐66 and 1 ± 2.9 points on the Peabody Gross Motor Quotient. Appropriately dosed, allogeneic partially or fully HLA‐matched sibling CB infusion is well tolerated and potentially beneficial in young children with CP.

Keywords

• cellular therapy
• clinical trials
• cord blood
• human cord blood
• nervous system
• umbilical cord blood